Cdkn2a (cyclin dependent kinase inhibitor 2A) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)
Gene: Cdkn2a (cyclin dependent kinase inhibitor 2A) Mus musculus
Analyze
Symbol: Cdkn2a
Name: cyclin dependent kinase inhibitor 2A
RGD ID: 10322
MGI Page MGI
Description: Enables DNA-binding transcription factor binding activity; MDM2/MDM4 family protein binding activity; and enzyme inhibitor activity. Involved in several processes, including negative regulation of lymphocyte proliferation; positive regulation of apoptotic process; and regulation of DNA-templated transcription. Acts upstream of or within several processes, including keratinocyte proliferation; negative regulation of mammary gland epithelial cell proliferation; and negative regulation of protein metabolic process. Located in cytoplasm and granular component. Part of protein-containing complex. Is expressed in several structures, including central nervous system; eye; genitourinary system; immune system; and umbilical artery. Used to study high grade glioma; malignant peripheral nerve sheath tumor; melanoma (multiple); and pancreatic carcinoma (multiple). Human ortholog(s) of this gene implicated in several diseases, including breast cancer (multiple); carcinoma (multiple); hematologic cancer (multiple); high grade glioma (multiple); and melanoma (multiple). Orthologous to human CDKN2A (cyclin dependent kinase inhibitor 2A).
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: A; alternative reading frame; Arf; ARF-; ARF-INK4a; CDK4I; cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; INK4; INK4a-ARF; Ink4a/Arf; mitochondrial smARF; MTS; MTS1; p1; p16; p16(INK4a); p16-INK4; p16-INK4a; p16I; p16INK4a; p19; p19; p19ARF; Pct; Pctr1
RGD Orthologs
Human
Rat
Bonobo
Dog
Pig
Alliance Orthologs
More Info more info ...
Latest Assembly: GRCm39 - Mouse Genome Assembly GRCm39
Position:
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm39489,192,710 - 89,212,856 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl489,192,708 - 89,212,890 (-)EnsemblGRCm39 Ensembl
GRCm38489,274,473 - 89,294,619 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl489,274,471 - 89,294,653 (-)EnsemblGRCm38mm10GRCm38
MGSCv37488,920,377 - 88,940,523 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36488,745,868 - 88,765,796 (-)NCBIMGSCv36mm8
Celera487,760,902 - 87,780,610 (-)NCBICelera
Cytogenetic Map4C4NCBI
cM Map442.15NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
acute lymphoblastic leukemia  (ISO)
acute myeloid leukemia  (ISO)
adenocarcinoma  (ISO)
Adrenal Gland Neoplasms  (ISO)
adrenocortical carcinoma  (ISO)
B-lymphoblastic leukemia/lymphoma  (IMP,ISO)
bone disease  (ISO)
Brain Neoplasms  (ISO)
Brain Stem Neoplasms  (ISO)
breast cancer  (ISO)
Breast Neoplasms  (ISO)
Carcinogenesis  (ISO)
cervix uteri carcinoma in situ  (ISO)
cholangiocarcinoma  (ISO)
Chromosome Deletion  (ISO)
chronic myeloid leukemia  (ISO)
chronic obstructive pulmonary disease  (ISO)
Colonic Neoplasms  (ISO)
Colorectal Neoplasms  (ISO)
diffuse large B-cell lymphoma  (ISO)
disease of cellular proliferation  (ISO)
dysplastic nevus syndrome  (ISO)
endometrial cancer  (ISO)
Endometrial Intraepithelial Neoplasia  (ISO)
Endometrial Neoplasms  (ISO)
esophageal carcinoma  (ISO)
Esophageal Neoplasms  (ISO)
esophagus adenocarcinoma  (ISO)
esophagus squamous cell carcinoma  (ISO)
Experimental Arthritis  (ISO)
Experimental Leukemia  (IMP)
Experimental Mammary Neoplasms  (IAGP,ISO)
familial melanoma  (ISO)
Familial Pancreatic Carcinoma  (ISO)
Fluoride Poisoning  (ISO)
gastric adenocarcinoma  (ISO)
Genetic Translocation  (ISO)
Germ Cell and Embryonal Neoplasms  (ISO)
germinoma  (ISO)
glaucoma  (ISO)
glioblastoma  (ISO)
granulosa cell tumor  (ISO)
head and neck squamous cell carcinoma  (ISO)
hepatocellular carcinoma  (ISO)
Hereditary Neoplastic Syndromes  (ISO)
high grade glioma  (ISO)
Hyperplasia  (ISO)
hypertension  (ISO)
in situ carcinoma  (ISO)
invasive ductal carcinoma  (ISO)
Kidney Neoplasms  (ISO)
leiomyosarcoma  (ISO)
leukemia  (ISO)
Liver Neoplasms  (ISO)
lung adenocarcinoma  (ISO)
Lung Neoplasms  (ISO)
lung non-small cell carcinoma  (ISO)
lung squamous cell carcinoma  (ISO)
Lymphatic Metastasis  (ISO)
lymphoma  (ISO)
Maffucci syndrome  (ISO)
malignant mesothelioma  (ISO)
melanoma  (IMP,ISO)
melanoma and neural system tumor syndrome  (ISO)
Melanoma-Pancreatic Cancer Syndrome  (ISO)
Mesothelioma  (ISO)
Micronuclei, Chromosome-Defective  (ISO)
Mouth Neoplasms  (ISO)
multiple myeloma  (ISO)
myelodysplastic syndrome  (ISO)
Neoplasm Invasiveness  (ISO)
Neoplasm Metastasis  (ISO)
nephroblastoma  (ISO)
Nerve Sheath Neoplasms  (ISO)
neurilemmoma  (ISO)
neuroblastoma  (ISO)
obesity  (ISO)
osteoarthritis  (ISO)
osteosarcoma  (ISO)
ovarian cancer  (ISO)
Ovarian Neoplasms  (ISO)
pancreatic adenocarcinoma  (ISO)
pancreatic cancer  (ISO)
pancreatic carcinoma  (ISO)
pancreatic ductal carcinoma  (ISO)
papillary renal cell carcinoma  (ISO)
papillomavirus infectious disease  (ISO)
peripheral nervous system disease  (ISO)
persistent hyperplastic primary vitreous  (IMP)
plasmacytoma  (IMP)
Pleural Effusion  (ISO)
Poisoning  (ISO)
pre-malignant neoplasm  (ISO)
Premature Aging  (IEP)
primary cutaneous T-cell non-Hodgkin lymphoma  (ISO)
prostate adenocarcinoma  (ISO)
prostate cancer  (ISO)
Prostatic Neoplasms  (IDA)
renal cell carcinoma  (ISO)
retinoblastoma  (ISO)
rhabdomyosarcoma  (ISO)
sarcomatoid mesothelioma  (ISO)
schizophrenia  (ISO)
Sezary's disease  (ISO)
skin melanoma  (ISO)
Sporadic Papillary Renal Cell Carcinoma  (ISO)
squamous cell carcinoma  (IAGP,ISO)
stomach cancer  (ISO)
Stomach Neoplasms  (ISO)
T-cell acute lymphoblastic leukemia  (IDA,IMP,ISO)
thymoma  (ISO)
Tongue Neoplasms  (ISO)
transient cerebral ischemia  (IEP)
transitional cell carcinoma  (ISO)
Trisomy  (ISO)
urinary bladder cancer  (ISO)
Urinary Bladder Neoplasm  (ISO)
Urogenital Neoplasms  (ISO)
uterine carcinosarcoma  (ISO)
Uterine Cervical Neoplasms  (ISO)
Vulvar Lichen Sclerosus  (ISO)
Vulvar Neoplasms  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-pilocarpine  (ISO)
(-)-epigallocatechin 3-gallate  (ISO)
(S)-naringenin  (ISO)
(S)-nicotine  (EXP)
(Z)-3-butylidenephthalide  (ISO)
1,2-dichloroethane  (EXP)
1,2-dimethylhydrazine  (EXP)
17beta-estradiol  (ISO)
17beta-hydroxy-17-methylestra-4,9,11-trien-3-one  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4-dinitrotoluene  (ISO)
2-acetamidofluorene  (ISO)
3-chloropropane-1,2-diol  (ISO)
4,4'-sulfonyldiphenol  (EXP,ISO)
4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one  (EXP)
4-hydroxyphenyl retinamide  (ISO)
4-phenylbutyric acid  (ISO)
4-vinylcyclohexene dioxide  (EXP)
5-aza-2'-deoxycytidine  (EXP,ISO)
5-azacytidine  (EXP,ISO)
5-fluorouracil  (ISO)
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide  (ISO)
6-propyl-2-thiouracil  (ISO)
7,12-dimethyltetraphene  (EXP)
aflatoxin B1  (ISO)
agomelatine  (ISO)
aldehydo-D-glucose  (ISO)
all-trans-retinoic acid  (ISO)
alpha-amanitin  (EXP)
alpha-D-galactose  (EXP,ISO)
ammonium chloride  (ISO)
amosite asbestos  (EXP)
anthra[1,9-cd]pyrazol-6(2H)-one  (EXP)
aristolochic acid A  (ISO)
arsane  (EXP,ISO)
arsenic atom  (EXP,ISO)
arsenite(3-)  (EXP,ISO)
arsenous acid  (ISO)
asbestos  (ISO)
belinostat  (ISO)
benzene  (ISO)
benzo[a]pyrene  (EXP,ISO)
benzo[b]fluoranthene  (EXP)
beryllium atom  (ISO)
beryllium dihydride  (ISO)
beryllium sulfate  (ISO)
beryllium(0)  (ISO)
bis(2-chloroethyl) sulfide  (ISO)
bis(2-ethylhexyl) phthalate  (EXP,ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (EXP)
BMS-754807  (ISO)
busulfan  (EXP)
Butylbenzyl phthalate  (EXP,ISO)
butyric acid  (EXP)
C60 fullerene  (ISO)
cadmium atom  (ISO)
cadmium dichloride  (ISO)
calcium dichloride  (ISO)
cannabidiol  (EXP,ISO)
capecitabine  (ISO)
capsaicin  (ISO)
carbon nanotube  (EXP,ISO)
carmustine  (ISO)
carteolol  (ISO)
casticin  (ISO)
chloramphenicol  (ISO)
chloroethene  (ISO)
chloroquine  (EXP)
chromium atom  (ISO)
chromium(6+)  (EXP,ISO)
chymostatin  (ISO)
cisplatin  (ISO)
clofibric acid  (ISO)
copper atom  (ISO)
copper(0)  (ISO)
copper(II) sulfate  (ISO)
cordycepin  (ISO)
corticosterone  (ISO)
crocidolite asbestos  (EXP,ISO)
curcumin  (ISO)
cycloheximide  (ISO)
cypermethrin  (ISO)
D-glucose  (ISO)
daunorubicin  (ISO)
DDT  (ISO)
dehydroepiandrosterone  (ISO)
Deoxycorticosterone acetate  (ISO)
desferrioxamine B  (ISO)
Diacetoxyscirpenol  (EXP)
diarsenic trioxide  (ISO)
dibutyl phthalate  (EXP,ISO)
dichloroacetic acid  (EXP)
dichromic acid  (ISO)
dichromium trioxide  (ISO)
dicoumarol  (ISO)
diethyl phthalate  (EXP)
diisobutyl phthalate  (EXP)
diisononyl phthalate  (EXP)
diisopropyl fluorophosphate  (ISO)
dimethylarsinic acid  (ISO)
dioscin  (ISO)
dioxygen  (ISO)
disodium selenite  (ISO)
diuron  (ISO)
dorsomorphin  (ISO)
doxorubicin  (EXP,ISO)
entinostat  (ISO)
ethanol  (EXP,ISO)
ethylparaben  (ISO)
etoposide  (EXP,ISO)
farrerol  (ISO)
fenbendazole  (ISO)
ferric ammonium citrate  (ISO)
ferric oxide  (EXP)
ferrostatin-1  (ISO)
fluoxetine  (EXP)
folic acid  (EXP,ISO)
fumonisin B1  (EXP)
furan  (ISO)
galactose  (EXP,ISO)
gamma-tocopherol  (ISO)
glucaric acid  (EXP)
glucose  (ISO)
glycidol  (ISO)
glycine betaine  (ISO)
glyphosate  (ISO)
GW 3965  (ISO)
GW 6471  (ISO)
harmine  (ISO)
hexachlorobenzene  (ISO)
hydralazine  (ISO)
hydrochlorothiazide  (ISO)
hydrogen peroxide  (ISO)
hydroquinone  (ISO)
hydroxyurea  (ISO)
imidacloprid  (EXP)
irbesartan  (EXP)
irinotecan  (ISO)
isocyanates  (EXP)
ivermectin  (ISO)
L-ascorbic acid  (ISO)
lead diacetate  (ISO)
lidocaine  (EXP)
linalool  (ISO)
lithium chloride  (ISO)
losartan  (ISO)
LY294002  (ISO)
maneb  (ISO)
masoprocol  (ISO)
Mecamylamine  (EXP)
melatonin  (ISO)
menadione  (ISO)
menaquinone  (ISO)
mercury dibromide  (ISO)
methamphetamine  (EXP,ISO)
methimazole  (ISO)
methoxyacetic acid  (ISO)
methoxychlor  (EXP)
methylmercury chloride  (EXP,ISO)
methylseleninic acid  (ISO)
microcystin RR  (ISO)
microcystin-LR  (ISO)
mono(2-ethylhexyl) phthalate  (EXP,ISO)
monobenzyl phthalate  (EXP,ISO)
Monobutylphthalate  (ISO)
monoethyl phthalate  (EXP,ISO)
monosodium L-glutamate  (EXP,ISO)
myo-inositol hexakisphosphate  (EXP)
N-acetyl-L-cysteine  (EXP,ISO)
N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal  (EXP)
N-ethyl-N-nitrosourea  (EXP)
N-methyl-4-phenylpyridinium  (ISO)
N-nitrosodiethylamine  (EXP,ISO)
N-nitrosodimethylamine  (ISO)
nickel dichloride  (ISO)
nickel subsulfide  (ISO)
nicotinamide  (EXP)
nicotine  (EXP)
nitrogen dioxide  (ISO)
NMN zwitterion  (ISO)
O-methyleugenol  (ISO)
ochratoxin A  (ISO)
oxaliplatin  (EXP)
ozone  (ISO)
p-menthan-3-ol  (ISO)
palbociclib  (EXP,ISO)
paracetamol  (ISO)
paraquat  (ISO)
parathion  (ISO)
perfluorohexanesulfonic acid  (EXP)
perfluorooctanoic acid  (ISO)
phenethyl caffeate  (ISO)
phenobarbital  (EXP)
phenylmercury acetate  (ISO)
PhIP  (ISO)
phorbol 13-acetate 12-myristate  (EXP,ISO)
pirinixic acid  (EXP,ISO)
piroxicam  (ISO)
potassium dichromate  (ISO)
prednisone  (ISO)
proanthocyanidin  (ISO)
procainamide  (ISO)
promethazine  (ISO)
pterostilbene  (EXP,ISO)
quercetin  (ISO)
radon atom  (ISO)
radon(0)  (ISO)
reserpine  (ISO)
resveratrol  (ISO)
S-(1,2-dichlorovinyl)-L-cysteine  (EXP)
salubrinal  (ISO)
SB 203580  (ISO)
SB 431542  (ISO)
sclareol  (ISO)
serpentine asbestos  (ISO)
silver(1+) nitrate  (ISO)
simvastatin  (ISO)
sodium arsenate  (ISO)
sodium arsenite  (EXP,ISO)
sodium dichromate  (EXP)
sodium fluoride  (EXP,ISO)
spironolactone  (ISO)
stavudine  (EXP)
streptozocin  (EXP)
sulforaphane  (EXP)
sulfur dioxide  (ISO)
sulindac  (ISO)
T-2 toxin  (ISO)
terephthalic acid  (ISO)
tetrachloromethane  (EXP)
thioacetamide  (ISO)
thioridazine  (ISO)
titanium dioxide  (EXP,ISO)
trichostatin A  (ISO)
triclosan  (ISO)
urethane  (EXP)
valproic acid  (ISO)
vincristine  (ISO)
vinorelbine  (ISO)
Withanone  (ISO)
wogonin  (ISO)
zearalenone  (ISO)
zidovudine  (EXP,ISO)
zinc pyrithione  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
amyloid fibril formation  (ISO)
apoptotic mitochondrial changes  (ISO)
apoptotic process involved in mammary gland involution  (IMP)
apoptotic signaling pathway  (ISO)
autophagy of mitochondrion  (ISO)
cellular response to glucose stimulus  (ISO)
cellular response to hydrogen peroxide  (IDA)
cellular senescence  (IDA,IGI,IMP,ISO)
cerebellum development  (ISO)
epidermis development  (IGI,IMP)
glucose homeostasis  (IMP)
keratinocyte differentiation  (IGI)
keratinocyte proliferation  (IGI)
mammary gland epithelial cell proliferation  (IMP)
mitochondrial depolarization  (ISO)
negative regulation of B cell proliferation  (IMP)
negative regulation of cell cycle  (IDA)
negative regulation of cell growth  (IMP,ISO)
negative regulation of cell population proliferation  (ISO)
negative regulation of cell-matrix adhesion  (ISO)
negative regulation of cyclin-dependent protein serine/threonine kinase activity  (IDA,ISO)
negative regulation of DNA-templated transcription  (ISO)
negative regulation of hepatocyte proliferation  (ISO)
negative regulation of immature T cell proliferation in thymus  (IMP)
negative regulation of mammary gland epithelial cell proliferation  (IMP)
negative regulation of NF-kappaB transcription factor activity  (ISO)
negative regulation of phosphorylation  (ISO)
negative regulation of protein localization to nucleolus  (IDA)
negative regulation of protein neddylation  (ISO)
negative regulation of proteolysis involved in protein catabolic process  (IDA,ISO)
negative regulation of ribosome biogenesis  (IDA)
negative regulation of ubiquitin protein ligase activity  (ISO)
negative regulation of ubiquitin-dependent protein catabolic process  (IDA,ISO)
negative regulation of ubiquitin-protein transferase activity  (IDA)
neurogenesis  (ISO)
nuclear body organization  (ISO)
oncogene-induced cell senescence  (IGI,IMP)
positive regulation of apoptotic process  (ISO,ISS)
positive regulation of apoptotic process involved in mammary gland involution  (IMP)
positive regulation of cysteine-type endopeptidase activity  (ISO)
positive regulation of DNA damage response, signal transduction by p53 class mediator  (IC,ISO)
positive regulation of DNA-binding transcription factor activity  (IMP)
positive regulation of DNA-templated transcription  (IMP,ISO)
positive regulation of gene expression  (ISO)
positive regulation of macrophage apoptotic process  (IGI)
positive regulation of protein localization to nucleus  (ISO)
positive regulation of protein sumoylation  (ISO)
positive regulation of signal transduction by p53 class mediator  (ISO)
positive regulation of smooth muscle cell apoptotic process  (IGI)
positive regulation of transcription by RNA polymerase II  (ISO)
protein destabilization  (ISO)
protein K63-linked ubiquitination  (ISO,ISS)
protein localization to nucleolus  (ISO)
protein localization to nucleus  (ISO)
protein polyubiquitination  (ISO,ISS)
protein stabilization  (ISO)
Ras protein signal transduction  (ISO)
regulation of apoptotic DNA fragmentation  (ISO)
regulation of cell cycle  (IDA,ISO)
regulation of cyclin-dependent protein serine/threonine kinase activity  (IDA)
regulation of DNA-binding transcription factor activity  (IGI)
regulation of G1/S transition of mitotic cell cycle  (ISO)
regulation of gene expression  (IMP)
regulation of nucleocytoplasmic transport  (IGI)
regulation of protein export from nucleus  (ISO)
regulation of protein stability  (IMP)
regulation of protein targeting to mitochondrion  (ISO)
replicative senescence  (ISO)
response to caloric restriction  (ISO)
response to fatty acid  (ISO)
response to organic cyclic compound  (ISO)
response to salt stress  (ISO)
response to xenobiotic stimulus  (ISO)
rRNA processing  (IEA)
rRNA transcription  (IGI)
somatic stem cell division  (IMP)
somatic stem cell population maintenance  (IGI)

Cellular Component

Phenotype Annotations     Click to see Annotation Detail View

Mammalian Phenotype
abnormal branching of the mammary ductal tree  (IAGP)
abnormal cell cycle  (IAGP)
abnormal cell physiology  (IAGP)
abnormal common myeloid progenitor cell morphology  (IAGP)
abnormal eye morphology  (IAGP)
abnormal forebrain development  (IAGP)
abnormal intestine morphology  (IAGP)
abnormal keratinocyte physiology  (IAGP)
abnormal lens capsule morphology  (IAGP)
abnormal lens development  (IAGP)
abnormal lens morphology  (IAGP)
abnormal mammary gland duct morphology  (IAGP)
abnormal melanocyte morphology  (IAGP)
abnormal melanocyte proliferation  (IAGP)
abnormal meninges morphology  (IAGP)
abnormal metabolism  (IAGP)
abnormal mitosis  (IAGP)
abnormal myogenesis  (IAGP)
abnormal nervous system morphology  (IAGP)
abnormal pancreas development  (IAGP)
abnormal pluripotent precursor cell morphology  (IAGP)
abnormal posterior eye segment morphology  (IAGP)
abnormal prostate gland physiology  (IAGP)
abnormal retina ganglion layer morphology  (IAGP)
abnormal retina inner nuclear layer morphology  (IAGP)
abnormal retina morphology  (IAGP)
abnormal retina neuronal layer morphology  (IAGP)
abnormal retina photoreceptor morphology  (IAGP)
abnormal skin development  (IAGP)
abnormal skin physiology  (IAGP)
abnormal somite development  (IAGP)
abnormal spermatocyte morphology  (IAGP)
abnormal spleen morphology  (IAGP)
abnormal spleen red pulp morphology  (IAGP)
abnormal telomere length  (IAGP)
abnormal tumor incidence  (IAGP)
abnormal vitreous body morphology  (IAGP)
ascites  (IAGP)
binocular blindness  (IAGP)
blindness  (IAGP)
cachexia  (IAGP)
cataract  (IAGP)
decreased body size  (IAGP)
decreased body weight  (IAGP)
decreased cell proliferation  (IAGP)
decreased incidence of tumors by chemical induction  (IAGP)
decreased testis weight  (IAGP)
decreased thymocyte number  (IAGP)
decreased tumor growth/size  (IAGP)
decreased tumor incidence  (IAGP)
decreased tumor latency  (IAGP)
decreased tumor-free survival time  (IAGP)
delayed cellular replicative senescence  (IAGP)
distended abdomen  (IAGP)
embryonic growth arrest  (IAGP)
embryonic growth retardation  (IAGP)
embryonic lethality during organogenesis, complete penetrance  (IAGP)
enhanced wound healing  (IAGP)
enlarged liver  (IAGP)
enlarged lymph nodes  (IAGP)
enlarged spleen  (IAGP)
epidermal hyperplasia  (IAGP)
extramedullary hematopoiesis  (IAGP)
hindlimb paralysis  (IAGP)
hunched posture  (IAGP)
hydrocephaly  (IAGP)
hyperkeratosis  (IAGP)
hyperpigmentation  (IAGP)
increased acute lymphoblastic leukemia incidence  (IAGP)
increased adenocarcinoma incidence  (IAGP)
increased B cell derived lymphoma incidence  (IAGP)
increased brain tumor incidence  (IAGP)
increased carcinoma incidence  (IAGP)
increased CD4-positive, alpha-beta T cell number  (IAGP)
increased CD8-positive, alpha-beta T cell number  (IAGP)
increased cell proliferation  (IAGP)
increased cellular sensitivity to ionizing radiation  (IAGP)
increased classified tumor incidence  (IAGP)
increased cutaneous melanoma incidence  (IAGP)
increased double-positive T cell number  (IAGP)
increased fibroblast proliferation  (IAGP)
increased fibrohistocytoma incidence  (IAGP)
increased fibrosarcoma incidence  (IAGP)
increased gastrointestinal stromal tumor incidence  (IAGP)
increased glioblastoma incidence  (IAGP)
increased glioma incidence  (IAGP)
increased hemangiosarcoma incidence  (IAGP)
increased histiocytic sarcoma incidence  (IAGP)
increased incidence of tumors by chemical induction  (IAGP)
increased incidence of tumors by ionizing radiation induction  (IAGP)
increased incidence of tumors by UV-induction  (IAGP)
increased intestinal adenoma incidence  (IAGP)
increased intraocular melanoma incidence  (IAGP)
increased keratinocyte migration  (IAGP)
increased keratinocyte proliferation  (IAGP)
increased leukemia incidence  (IAGP)
increased liver tumor incidence  (IAGP)
increased lung adenocarcinoma incidence  (IAGP)
increased lung carcinoma incidence  (IAGP)
increased lung tumor incidence  (IAGP)
increased lymphoma incidence  (IAGP)
increased male germ cell apoptosis  (IAGP)
increased malignant tumor incidence  (IAGP)
increased melanoma incidence  (IAGP)
increased meningioma incidence  (IAGP)
increased mesothelioma incidence  (IAGP)
increased metastatic potential  (IAGP)
increased neurofibrosarcoma incidence  (IAGP)
increased neuron apoptosis  (IAGP)
increased oligodendroglioma incidence  (IAGP)
increased osteoma incidence  (IAGP)
increased osteosarcoma incidence  (IAGP)
increased pancreas adenoma incidence  (IAGP)
increased pancreas tumor incidence  (IAGP)
increased pancreatic ductal adenocarcinoma incidence  (IAGP)
increased pancreatic intraepithelial neoplasia incidence  (IAGP)
increased papilloma incidence  (IAGP)
increased prostate gland adenocarcinoma incidence  (IAGP)
increased rhabdomyosarcoma incidence  (IAGP)
increased sarcoma incidence  (IAGP)
increased satellite cell number  (IAGP)
increased Schwannoma incidence  (IAGP)
increased skin squamous cell carcinoma incidence  (IAGP)
increased skin tumor incidence  (IAGP)
increased small lymphocytic lymphoma incidence  (IAGP)
increased spindle cell carcinoma incidence  (IAGP)
increased spleen white pulp amount  (IAGP)
increased splenocyte proliferation  (IAGP)
increased squamous cell carcinoma incidence  (IAGP)
increased stomach tumor incidence  (IAGP)
increased T cell derived lymphoma incidence  (IAGP)
increased testis weight  (IAGP)
increased thymus weight  (IAGP)
increased tumor growth/size  (IAGP)
increased tumor incidence  (IAGP)
increased uterus leiomyoma incidence  (IAGP)
intestinal fibrosis  (IAGP)
jaundice  (IAGP)
kyphosis  (IAGP)
lung hemorrhage  (IAGP)
male infertility  (IAGP)
mammary gland duct hyperplasia  (IAGP)
microphthalmia  (IAGP)
oligozoospermia  (IAGP)
osseous metaplasia  (IAGP)
pancreas cyst  (IAGP)
paralysis  (IAGP)
persistent hyperplastic primary vitreous  (IAGP)
pleural effusion  (IAGP)
premature aging  (IAGP)
premature death  (IAGP)
prenatal lethality, complete penetrance  (IAGP)
preweaning lethality, complete penetrance  (IAGP)
primary vitreous hyperplasia  (IAGP)
prostate gland hyperplasia  (IAGP)
retina detachment  (IAGP)
retina fold  (IAGP)
seizures  (IAGP)
skeletal muscle hyperplasia  (IAGP)
skeletal muscle interstitial fibrosis  (IAGP)
skin fibrosis  (IAGP)
skin lesions  (IAGP)
testicular atrophy  (IAGP)
thymus hyperplasia  (IAGP)
weight loss  (IAGP)
References

References - curated
# Reference Title Reference Citation
1. Rearrangement and allelic imbalance on chromosome 5 leads to homozygous deletions in the CDKN2A/2B tumor suppressor gene region in rat endometrial cancer. Adamovic T, etal., Cancer Genet Cytogenet. 2008 Jul;184(1):9-21.
2. Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors. Arcellana-Panlilio MY, etal., Genes Chromosomes Cancer. 2002 Oct;35(2):176-81.
3. Promoter hypermethylation of tumour suppressor genes (p14/ARF and p16/INK4a): case-control study in North Indian population. Askari M, etal., Mol Biol Rep. 2013 Aug;40(8):4921-8. doi: 10.1007/s11033-013-2592-5. Epub 2013 May 28.
4. p16 hypermethylation during gastric carcinogenesis of Wistar rats by N-methyl-N'-nitro-N-nitrosoguanidine. Bai H, etal., Mutat Res. 2003 Feb 5;535(1):73-8.
5. Aberrant CpG island methylation of the p16(INK4a) and estrogen receptor genes in rat lung tumors induced by particulate carcinogens. Belinsky SA, etal., Carcinogenesis 2002 Feb;23(2):335-9.
6. Immunohistochemical expression of p16(INK4a) is predictive of HR-HPV infection in cervical low-grade lesions. Benevolo M, etal., Mod Pathol. 2006 Mar;19(3):384-91.
7. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. Borg A, etal., J Natl Cancer Inst. 2000 Aug 2;92(15):1260-6.
8. Expression of the cell cycle regulators p53, p21(WAF1/CIP1) and p16(INK4a) in human endometrial adenocarcinoma. Buchynska LG and Nesina IP, Exp Oncol. 2006 Jun;28(2):152-5.
9. p14ARF and p16INK4A, two products of the same gene, are differently expressed in cervical intraepithelial neoplasia. Bulten J, etal., Gynecol Oncol. 2006 Jun;101(3):487-94. Epub 2006 Jan 9.
10. Role of INK4a locus in normal eye development and cataract genesis. Cheong C, etal., Mech Ageing Dev. 2006 Jul;127(7):633-8. Epub 2006 Apr 18.
11. The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome. Chien WW, etal., Leuk Res. 2015 Apr;39(4):453-61. doi: 10.1016/j.leukres.2015.01.008. Epub 2015 Jan 25.
12. Expression of the cell cycle regulators p14(ARF) and p16(INK4a) in chronic myeloid leukemia. Cividin M, etal., Leuk Res. 2006 Oct;30(10):1273-8. Epub 2006 Mar 14.
13. Prevalence of mucosal and cutaneous human papillomaviruses in different histologic subtypes of vulvar carcinoma. de Koning MN, etal., Mod Pathol. 2008 Jan 11;.
14. Novel CDKN2A mutation detected in Spanish melanoma pedigree. de Torre C and Martinez-Escribano J, Exp Dermatol. 2010 Aug;19(8):e333-5. doi: 10.1111/j.1600-0625.2009.01048.x.
15. Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss. Debies MT, etal., J Clin Invest. 2008 Jan;118(1):51-63.
16. A common variant of CDKN2A (p16) predisposes to breast cancer. Debniak T, etal., J Med Genet. 2005 Oct;42(10):763-5. Epub 2005 May 6.
17. Population-based prevalence of CDKN2A mutations in Utah melanoma families. Eliason MJ, etal., J Invest Dermatol. 2006 Mar;126(3):660-6.
18. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Faderl S, etal., Cancer. 2000 Nov 1;89(9):1976-82.
19. p16INK4A tumor suppressor gene expression and CD3epsilon deficiency but not pre-TCR deficiency inhibit TAL1-linked T-lineage leukemogenesis. Fasseu M, etal., Blood. 2007 Oct 1;110(7):2610-9. Epub 2007 May 16.
20. Immunohistochemical expression of p16(INK4A) in normal uterine cervix, nonneoplastic epithelial lesions, and low-grade squamous intraepithelial lesions. Focchi GR, etal., J Low Genit Tract Dis. 2007 Apr;11(2):98-104.
21. Early deregulation of the the p16ink4a-cyclin D1/cyclin-dependent kinase 4-retinoblastoma pathway in cell proliferation-driven esophageal tumorigenesis in zinc-deficient rats. Fong LY, etal., Cancer Res. 2000 Aug 15;60(16):4589-95.
22. Differential Immunoreactivity of p16 in leiomyosarcomas and leiomyoma variants. Gannon BR, etal., Int J Gynecol Pathol. 2008 Jan;27(1):68-73.
23. High frequency of aberrant p16(INK4A) expression in human breast cancer. Geradts J and Wilson PA, Am J Pathol. 1996 Jul;149(1):15-20.
24. Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma. Guillerm G, etal., Haematologica. 2003 Apr;88(4):476-8.
25. Melanoma development in relation to non-functional p16/INK4A protein and dysplastic naevus syndrome in Swedish melanoma kindreds. Hashemi J, etal., Melanoma Res. 1999 Feb;9(1):21-30.
26. Loss of p19Arf in a Rag1(-/-) B-cell precursor population initiates acute B-lymphoblastic leukemia. Hauer J, etal., Blood. 2011 Jul 21;118(3):544-53. doi: 10.1182/blood-2010-09-305383. Epub 2011 May 26.
27. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors. Heidenreich A, etal., J Urol. 1998 May;159(5):1725-30.
28. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Herman JG, etal., Cancer Res. 1996 Feb 15;56(4):722-7.
29. Specific allelic loss of p16 (INK4A) tumor suppressor gene after weeks of iron-mediated oxidative damage during rat renal carcinogenesis. Hiroyasu M, etal., Am J Pathol 2002 Feb;160(2):419-24.
30. Frequent mutation of p16(CDKN2A) exon 1 during rat tongue carcinogenesis induced by 4-nitroquinoline-1-oxide. Hong Y, etal., Mol Carcinog. 2007 Feb;46(2):85-90.
31. p16(CDKN2A) expression during rat tongue carcinogenesis induced by 4-nitroquinoline-1-oxide. Hong Y, etal., Oral Oncol. 2009 Jul;45(7):640-4. doi: 10.1016/j.oraloncology.2008.06.007. Epub 2008 Sep 18.
32. Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma. Hu Q, etal., Lab Invest. 2010 Mar;90(3):360-73. doi: 10.1038/labinvest.2009.140. Epub 2010 Jan 11.
33. Expression of p16(INK4A) induces dominant suppression of glioblastoma growth in situ through necrosis and cell cycle arrest. Hung KS, etal., Biochem Biophys Res Commun. 2000 Mar 24;269(3):718-25.
34. DNA copy number aberrations and disruption of the p16Ink4a/Rb pathway in radiation-induced and spontaneous rat mammary carcinomas. Iizuka D, etal., Radiat Res. 2010 Aug;174(2):206-15. doi: 10.1667/RR2006.1.
35. Frequent p16ink4a inactivation is an early and frequent event of intraductal papillary neoplasm of the liver arising in hepatolithiasis. Ishikawa A, etal., Hum Pathol. 2004 Dec;35(12):1505-14.
36. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Jones S, etal., Science. 2008 Sep 26;321(5897):1801-6. Epub 2008 Sep 4.
37. Methylation of p16INK4a is a non-rare event in cervical intraepithelial neoplasia. Kang S, etal., Diagn Mol Pathol. 2006 Jun;15(2):74-82.
38. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Kannan K, etal., Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1221-5. Epub 2003 Jan 21.
39. Homozygous deletions of the INK4a/ARF locus in renal cell cancer. Kasahara T, etal., Anticancer Res. 2006 Nov-Dec;26(6B):4299-305.
40. Mild cerebral ischemia induces loss of cyclin-dependent kinase inhibitors and activation of cell cycle machinery before delayed neuronal cell death. Katchanov J, etal., J Neurosci. 2001 Jul 15;21(14):5045-53.
41. Molecular targeting of neuroblastoma with a novel p16INK4a transporter system. Kawaguchi T, etal., Int J Oncol. 2014 Jun;44(6):1879-85. doi: 10.3892/ijo.2014.2372. Epub 2014 Apr 7.
42. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Kawamoto K, etal., Biochem Biophys Res Commun. 2006 Jan 20;339(3):790-6. Epub 2005 Nov 22.
43. Methylation of the p16INK4A promoter is associated with malignant behavior in abdominal extra-adrenal paragangliomas but not pheochromocytomas. Kiss NB, etal., Endocr Relat Cancer. 2008 Jun;15(2):609-21. doi: 10.1677/ERC-07-0285.
44. Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Kommoss S, etal., Br J Cancer. 2007 Jan 29;96(2):306-13.
45. Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas. Labuhn M, etal., Oncogene. 2001 Mar 1;20(9):1103-9.
46. CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Laharanne E, etal., Mod Pathol. 2010 Apr;23(4):547-58. doi: 10.1038/modpathol.2009.196. Epub 2010 Jan 29.
47. p16INK4A-silencing augments DNA damage-induced apoptosis in cervical cancer cells. Lau WM, etal., Oncogene. 2007 Sep 6;26(41):6050-60. Epub 2007 Mar 19.
48. Dynamic changes in DNA methylation during multistep rat lung carcinogenesis induced by 3-methylcholanthrene and diethylnitrosamine. Liu WB, etal., Toxicol Lett. 2009 Aug 25;189(1):5-13. doi: 10.1016/j.toxlet.2009.04.022. Epub 2009 May 3.
49. [Loss of heterozygosity in the 9p21 region as an inactivation mechanism of the p16 suppressor gene]. Maestro de las Casas ML, etal., Arch Esp Urol. 2000 Sep;53(7):603-9.
50. Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Maloney KW, etal., Blood. 1999 Apr 1;93(7):2380-5.
51. Lack of ETV6 (TEL) gene rearrangements or p16INK4A/p15INK4B homozygous gene deletions in infant acute lymphoblastic leukemia. Maloney KW, etal., Leukemia. 1997 Jul;11(7):979-83.
52. Carcinogen exposure and epigenetic silencing in bladder cancer. Marsit CJ, etal., Ann N Y Acad Sci. 2006 Sep;1076:810-21.
53. Electronic Transfer of Homolog Data MGD and Homologene mouse data transfer
54. MGDs mouse GO annotations MGD data from the GO Consortium
55. MGD IEA MGD IEA
56. P16(INK4a) immunocytochemistry in liquid-based cytology samples in equivocal Pap smears: added value in management of women with equivocal Pap smear. Monsonego J, etal., Acta Cytol. 2007 Sep-Oct;51(5):755-66.
57. DNA methylation pathway alterations in an autochthonous murine model of prostate cancer. Morey SR, etal., Cancer Res. 2006 Dec 15;66(24):11659-67.
58. Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: mutations of CDKN2 are observed preferentially in T lineage. Nakao M, etal., Leukemia. 1996 Feb;10(2):249-54.
59. Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours. Natrajan R, etal., J Clin Pathol. 2008 Jan;61(1):95-102. Epub 2007 Mar 16.
60. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Nielsen GP, etal., Am J Pathol 1999 Dec;155(6):1879-84.
61. Immunohistochem